Kroatië - Kroatisch - HALMED (Agencija za lijekove i medicinske proizvode)

alkaloid - int d.o.o., Šlandrova ulica 4, ljubljana, slovenija - memantinklorid - filmom obložena tableta - 5 mg - urbroj: jedna filmom obložena tableta sadrži 5 mg memantinklorida, što odgovara 4,15 mg memantina

Bosnië en Herzegovina - Kroatisch - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

pharmavision bh d.o.o. - acetilcistein - prašak za oralni rastvor - 200 mg/1 kesica - jedna kesica sa praškom za oralni rastvor sadrži: 200 mg acetilcisteina

Bosnië en Herzegovina - Kroatisch - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

pharmavision bh d.o.o. - acetilcistein - prašak za oralni rastvor - 600 mg/1 kesica - jedna kesica sa praškom za oralni rastvor sadrži: 600 mg acetilcisteina

Europese Unie - Kroatisch - EMA (European Medicines Agency)

novartis europharm limited - ribociklib sukcinata - neoplazme dojki - antineoplastična sredstva - kisqali je indiciran za liječenje žena s hormon receptor (h)‑pozitivan, людское эпидермическое ako uređaj primatelja 2 faktor rasta (her2)‑negativan lokalno-uobičajena ili metastatskih tumora dojke u kombinaciji s inhibitor aromataze, ili fulvestrant kao izvor endokrine terapije na temelju ili u žene koje su primili do hormonske terapije. u pre‑ ili perimenopauzi, endokrini terapija mora biti u kombinaciji s luteinizirajućeg hormona releasing hormon (lhrh) agonist.

Europese Unie - Kroatisch - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastična sredstva - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Kroatië - Kroatisch - HALMED (Agencija za lijekove i medicinske proizvode)

diahem d.o.o., velika gorica - in vitro dijagnostika, uređaji za pripremu uzoraka

Kroatië - Kroatisch - HALMED (Agencija za lijekove i medicinske proizvode)

diahem d.o.o., velika gorica - reagensi za određivanje krvnih grupa, rh faktora i antitijela

Kroatië - Kroatisch - HALMED (Agencija za lijekove i medicinske proizvode)

diahem d.o.o., velika gorica - in vitro dijagnostika, uređaji za čitanje kartica

Europese Unie - Kroatisch - EMA (European Medicines Agency)

zoetis belgium sa - maropitant citrat - opskrbni sustav i metabolizam - dogs; cats - tablete psi: za sprečavanje mučnine uzrokovane kemoterapijom. za sprečavanje povraćanja uzrokovanih bolesti kretanja. za sprečavanje i liječenje povraćanja, zajedno s cerenia otopinom za injekcije i u kombinaciji s drugim potpornim mjerama. rješenje za injectiondogs:za liječenje i prevenciju mučnine uzrokovane kemoterapijom. za sprečavanje povraćanja osim onog uzrokovanog mučninom. za liječenje povraćanja, u kombinaciji s drugim potpornim mjerama. za prevenciju perioperativne mučnine i povraćanja i poboljšanja oporavka od opće anestezije nakon uporabe agonista morfina μ-opijatnog receptora. mačke: za sprečavanje povraćanja i smanjenje mučnine, osim onog uzrokovanog mučninom. za liječenje povraćanja, u kombinaciji s drugim potpornim mjerama.

Europese Unie - Kroatisch - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - cjepiva - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama.